IMMray™ PanCan-d clinical studies ongoing – Immunovia

Pancreatic cancer

Clinical need

While pancreatic cancer, also known as pancreatic adenocarcinoma, is only the 14th most common cancer, it is the 4th most deadly. Its 5-year survival rate is less than 4%. This poor prognosis could be significantly improved if cases were detected and treated early. The cancer is, however, characterized by general and non-specific symptoms until it reaches an advanced stage, by which time current therapy is not effective. In addition, current methods for diagnosis are complex and not designed for differential diagnosis at an early stage. Hence, there is a great clinical need for novel non-invasive tests enabling early (differential) diagnosis.

Solution provided by Immunovia

IMMray™ PanCand is the first blood-based test for early and specific (differential) diagnosis, providing clinicians with actionable information. Immunovia has defined a clinically relevant condensed panel of serum biomarkers (a biomarker signature) associated with pancreatic adenocarcinoma. This biomarker panel can be used for differential diagnosis at an early stage of the cancer. The test is suitable for screening risk-groups as well as investigating patients with suspected symptoms.

IMMray™ PanCand  is in its late development phase. We are currently planning and conducting several clinical evidence studies in collaboration with leading cancer centers around the world and the results and summary of these studies are presented on  the next page: Clinical evidence studies overview.

In 2015, a multicenter retrospective study that covered 1400 blood samples from individuals with pancreatic cancer stages I to IV and matched controls was completed in Lund, Sweden. The study demonstrated that IMMray™ PanCan-d test is able to differentiate with 96% accuracy patients the early resectable stages of pancreatic cancer, stage I and II, from the healthy controls. When analyzing all stages of pancreatic cancer, the accuracy of Immunovia´s test is reported as high as 98%. The centers involved in this study were: Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark, Department of Immunotechnology, Lund University, Sweden, CREATE Health, Lund University, Sweden, CREATE Health Translational Cancer Center in collaboration with Immunovia, Lund, Sweden.

From the patients’ perspective, this new biomarker will facilitate early detection of pancreatic cancer, even in asymptomatic stages, thereby helping increase survivability rates from 3-5% to 50-60%. The introduction of the new signature into routine screening could make early pancreatic cancer detection both practical and standardized.


1) Ingvarsson, J., Wingren, C., Carlsson, A., Ellmark, P., Wahren, B., Engström, G., Harmenberg, U., Krogh, M., Peterson, C., and Borrebaeck, C.A.K., Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics. 2008, 8, 2211-2219

2) Wingren C, Sandström A, Segersvärd R, Carlsson A, Andersson R, Löhr M, Borrebaeck CAK Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Research, 2012, 72, 2481-2490.

3) Sandström, A., Andersson, R., Segersvärd, R., Löhr, M., Borrebaeck, CAK., and Wingren C., Serum protein profiling of pancreatitis using recombinant antibody microarrays reveals disease-associated biomarker signatures. Proteomics – Clinical Applications. 2012, 6, 486-496.